VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice
about
Autosomal dominant polycystic kidney disease: the last 3 yearsPolycystic liver diseases: advanced insights into the molecular mechanismsExperimental therapies and ongoing clinical trials to slow down progression of ADPKDImmunohistochemical expression of vascular endothelial growth factor in orofacial lesions - A reviewHepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney diseaseIsolated polycystic liver disease.Regulators of Cholangiocyte Proliferation.Polycystic liver diseases.Treatment strategies and clinical trial design in ADPKDAn mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.CXCR2 agonists in ADPKD liver cyst fluids promote cell proliferation.ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice.Regulation of biliary proliferation by neuroendocrine factors: implications for the pathogenesis of cholestatic liver diseases.Hypoxia-inducible factor-1α (HIF-1α) and autophagy in polycystic kidney disease (PKD).Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathwayThe role of vascular endothelial growth factor in proliferation of odontogenic cysts and tumors: An immunohistochemical study.Cholangiocyte proliferation and liver fibrosis.Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease.Advances in management of polycystic liver disease.Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.Systematic review: the pathophysiology and management of polycystic liver disease.Angiogenesis and autosomal dominant polycystic kidney disease.Diagnosis and management of polycystic liver disease.Therapeutic Targets in Polycystic Liver Disease.An update on the pathophysiology and management of polycystic liver disease.New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis.Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib.Primary cilia disruption differentially affects the infiltrating and resident macrophage compartment in the liver.
P2860
Q24656249-2DA4CAAB-EAB8-45E5-84B4-7E97161685A7Q27001174-4429585C-40F0-4B83-822D-1570050ED28BQ27001230-B9F73918-1F69-430F-87A2-04B4E5AC2494Q28066284-444D8276-5839-4F8C-BE20-C1E9567D24B0Q28569447-A75E1B8D-EEFB-4691-9A19-094BA500AEC2Q33723830-CA89B8FE-4CE3-4B8F-AFFC-7A35496A4888Q33863341-B456A7D1-6B6A-4484-80B9-D33B71165D95Q33949172-208CC6D9-70B9-40E2-92A9-388850B16A4AQ34024396-E0E1813A-7316-4E1D-A561-26EFEACB861EQ34074513-83D9D79B-EC2D-4D79-9311-8851ACE4BC6AQ34208664-0FE0E784-9A37-4BCE-AA59-34C0E731806FQ34399971-C9704A24-4B98-4E42-8523-A26D038B1EBAQ34755613-4B26DF2C-D2E8-4A31-93F1-95201E97C4F3Q34979642-3EB23E69-D781-4897-9792-F31A9CE7C64FQ35086449-1568BD7A-A9D8-4392-977D-6FDDD54B52D4Q35981512-7946FD72-E28A-49C7-8F95-06630494BEE1Q36930252-5D91ED7C-9FB9-4535-A704-C994E9231EE3Q37175438-7C6428D7-2883-4134-94E5-D35F2B099705Q37273720-83951A51-4830-4C7D-AEF6-0D9E2F1D496AQ37345965-8FA4156A-DDC1-41F2-9842-88A2DDFCF2C4Q37760379-F8E21090-EDF3-455C-99D4-610D705A2D83Q37905881-08DF0320-D6D7-4CA6-8936-14471B4B853FQ38044599-D854578C-A6CB-4E3B-A0B2-4E1FADAF3879Q38072284-99343C71-ACA0-4B56-9F40-5E5624704187Q38443908-7E0673AF-F236-488F-971E-F4FAF0E7447EQ39186912-EB1D0D17-3783-4830-9DC9-B08DBA95B808Q41853468-C3BBE7AF-3CA8-4A5F-A4E7-B2F49E541952Q42213282-86ABA382-D1A2-4F94-8DA2-027C2EB104D0Q51739818-83EF5109-8DCD-4AA4-A563-42D7647D4182
P2860
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice
description
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2007
@ast
im Juli 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2007/07/01)
@sk
vědecký článek publikovaný v roce 2007
@cs
wetenschappelijk artikel (gepubliceerd op 2007/07/01)
@nl
наукова стаття, опублікована в липні 2007
@uk
مقالة علمية (نشرت في يوليو 2007)
@ar
name
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice
@ast
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice
@en
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice
@nl
type
label
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice
@ast
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice
@en
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice
@nl
prefLabel
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice
@ast
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice
@en
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice
@nl
P2093
P2860
P1476
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice
@en
P2093
Kelley S Brodsky
Norbert F Voelkel
R Brian Doctor
Rachel Groff
Vincent H Gattone
P2860
P304
P356
10.1152/AJPCELL.00038.2007
P50
P577
2007-05-02T00:00:00Z